"The environment at Genentech is always stimulating and the opportunity to work with some of the brightest and most innovative scientists imaginable working toward a common and urgent goal of providing new and better options for patients is continuously rewarding. The urgency of our mission drives us to bring our best selves to work every day."
Following completion of residency training in Pathology and post-doctoral work in Endocrine Pathology, I joined Genentech as a Scientist-Pathologist in 1992. I was most attracted by the Genentech reputation for rigor. Happily, given my interest and training in pathology, receptor ligand biology and radioimmunoassay and immunohistochemistry techniques, I became involved early with the oncology program teams, in particular the anti-HER2 projects. My responsibilities have also included growing the Safety Assessment Pathology group to meet the needs of all Genentech programs.
Breast Cancer Res Treat. 2005 Sep; 93(1): 3-11.
Providing expertise in pathology, veterinary medicine and comparative medicine to enhance the timely development of safe Genentech medicines. Working in a highly collaborative environment with colleagues from across the gRED and Product Development to design and implement programs in support of optimal drug candidate development at Genentech. Building and supporting an industry leading Safety Assessment Pathology group. Actively driving innovation in preclinical drug development approaches, supporting and participating in internal and cross-industry efforts to increase drug development efficiency and success while building data to support regulatory acceptance.